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A B S T R A C T
Introduction: Faecal incontinence aﬀects approximately 8–9% of the adult population. The condition is sur-
rounded by taboo; it can have a devastating impact on quality of life and lead to major limitations in daily life.
Pelvic ﬂoor muscle training in combination with information and ﬁbre supplements is recommended as ﬁrst-line
treatment for faecal incontinence. Despite this, the eﬀect of pelvic ﬂoor muscle training for faecal incontinence is
unclear. No previous trials have investigated the eﬃcacy of supervised pelvic ﬂoor muscle training in combi-
nation with conservative treatment and compared this to an attention-control massage treatment including
conservative treatment. The aim of this trial is to investigate if 16 weeks of supervised pelvic ﬂoor muscle
training in combination with conservative treatment is superior to attention-control massage treatment and
conservative treatment in patients with faecal incontinence.
Design: Randomised, controlled, superiority trial with two parallel arms.
Methods: 100 participants with faecal incontinence will be randomised to either (1) individually supervised
pelvic ﬂoor muscle training and conservative treatment or (2) attention-control massage treatment and con-
servative treatment. The primary outcome is participants' rating of symptom changes after 16 weeks of treatment
using the Patient Global Impression of Improvement Scale. Secondary outcomes are the Vaizey Incontinence
Score, the Fecal Incontinence Severity Index, the Fecal Incontinence Quality of Life Scale, a 14-day bowel diary,
anorectal manometry and rectal capacity measurements. Follow-up assessment at 36 months will be conducted.
Discussion: This paper describes and discusses the rationale, the methods and in particular the statistical analysis
plan of this trial.
1. Introduction
Faecal incontinence is the complaint of involuntary loss of faeces
[1] and aﬀects approximately 8–9% of the adult population [2,3]. It is a
hidden problem – many people are suﬀering in silence since they are
reluctant to reveal their situation [4–7]. The condition can have a de-
vastating impact on quality of life [4,6,8–12] and lead to major lim-
itations in daily life [6,8–11]. In qualitative studies, living with faecal
incontinence is described as an everlasting ﬁght for controlling and
hiding a condition that is out of control [8–10].
Faecal incontinence is a multifactorial condition. The recommended
ﬁrst-line treatment consists of a multi-modal approach including: in-
formation, ﬁbre supplements, antidiarrhoeal medication, laxatives,
pelvic ﬂoor muscle training (PFMT) and biofeedback training [13–17].
PFMT is deﬁned as ‘systematic training with repeated voluntary con-
tractions of the pelvic ﬂoor muscles and the external anal sphincter
http://dx.doi.org/10.1016/j.conctc.2017.07.006
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with the purpose of increasing muscle strength, speed, endurance and/
or coordination’ [13,16,18]. In most trials, PFMT is supplemented with
biofeedback training in form of ‘strength training’ and/or ‘rectal sen-
sitivity training’ [13,17–19].
A recent systematic Cochrane review [13] included 20 randomised
controlled trials to investigate the eﬃcacy of PFMT and/or biofeedback
training for the treatment of faecal incontinence in adults. With the
exception of two trials that evaluated PFMT and biofeedback training in
conjunction with an operation, the included trials compared diﬀerent
training modalities and thus lacked a non-training comparator [13].
This limits the ability to conclude on the ‘true’ eﬃcacy of PFMT and
biofeedback training. Due to risk of bias, intervention heterogeneity
and the use of diﬀerent comparators, the authors of the Cochrane re-
view concluded that the role of PFMT and biofeedback training for
treatment of faecal incontinence is unclear [13]. Two trials published
after the Cochrane review [20,21] evaluated the eﬀect of PFMT and
biofeedback training compared to a group not receiving PFMT. How-
ever, neither trial controlled for the possible placebo eﬀect associated
with the attention given by the health care professional delivering the
training interventions [20,21]. To evaluate the eﬃcacy of PFMT, there
is a need for a trial that uses an attention-control treatment, which is
biologically ineﬀective, but controls for the placebo eﬀect associated
with the attention given by the health care professional delivering the
PFMT. To our knowledge, no previous trials have investigated the ef-
ﬁcacy of supervised PFMT in combination with conservative treatment
and compared this to an attention-control massage treatment in addi-
tion to conservative treatment.
The aim of the current trial is to investigate if supervised PFMT in
combination with conservative treatment (mainly information) is su-
perior to attention-control massage-treatment in combination with the
same conservative treatment in patients with faecal incontinence. This
possible superiority eﬀect is based on the primary outcome of changes
in faecal incontinence symptoms after 16 weeks of treatment using The
Patient Global Impression of Improvement Scale (PGI-I). The aim of this
paper is to describe the rationale, the methods, and in particular the
statistical analysis plan of this trial, so that this information is made
public.
2. Methods
2.1. Design of the trial
The trial is a prospective, outcome assessor-blinded, randomised,
controlled, superiority trial with two parallel arms. Outcome measures
will be assessed at baseline (before treatment start) and after 16 weeks
of treatment (end of treatment period, primary endpoint) and at a long-
term follow-up 36 months after completing the treatments. From
January 1, 2016, 98 participants are randomised into two groups (su-
pervised PFMT and attention-control massage treatment) by simple
randomisation, using a ratio of 1:1. Data for the primary analysis
(baseline plus the 16-week outcome assessment) will be collected from
October 24, 2012 until June 17, 2016. Data for the 36-months follow-
up will be collected until June 2019. Currently, no analyses have been
performed and treatment group allocation remains blinded. This pro-
tocol and statistical analysis plan is reported in accordance with the
SPIRIT 2013 Statement: Standard Protocol items: Recommendation for
Interventional Trials [22] (See the completed SPIRIT checklist attached
as Additional ﬁle 1). The description of the intervention follows the
Template for Intervention Description and Replication (TIDieR)
checklist [23]. Once completed, the reporting of the trial will follow the
Consolidated Standards of Reporting Trials (CONSORT) checklist [24],
using the extension for non-pharmacological interventions [25] sup-
plemented with the TIDieR-checklist for intervention description [23].
The trial was preregistered at ClinicalTrials.gov ID: NCT01705535,
https://clinicaltrials.gov/ct2/show/NCT01705535, registration date:
October 10, 2012.
2.2. Participants and settings
The trial is ongoing at Copenhagen University Hospital, Hvidovre,
Denmark in a collaborative eﬀort between the Department of
Physiotherapy- and Occupational Therapy and the Department of
Surgical and Medical Gastroenterology. Between October 15, 2012 and
December 15, 2015, consecutive patients referred for examination and
treatment of faecal incontinence at the Department of Surgical and
Medical Gastroenterology will be assessed for eligibility. We aim to
include 100 participants, based on estimations described in the ‘sample
size’ section. At the ﬁrst visit with a specialised nurse, eligible patients
will be brieﬂy informed about the trial. Patients interested in the trial
will be invited to a second visit at the Department of Physiotherapy-
and Occupational Therapy where they will receive thorough verbal and
written information about the trial. The enrolment is handled by the
primary investigator (AU) who is blinded with respect to allocation to
trial arms and not involved in the assessment of outcomes. Before en-
rolment, the participants will submit written informed consents ac-
cording to the Declaration of Helsinki.
Inclusion: The inclusion criteria are: faecal incontinence for at least
6 months and age ≥18 years.
Exclusion: The exclusion criteria are: pregnancy, chronic diarrhoea,
severe neurological disease (Multiple Sclerosis, Parkinson's disease,
spinal cord injury, major stroke or neuromuscular junction diseases)
rectal prolapse, previous operation for cancer or radiotherapy in the
lower abdomen, inadequate Danish, cognitively unable to perform
PFMT and more than two sessions of individually supervised PFMT
within the last 12 months.
2.3. Randomisation, allocation and concealment
Once included, baseline assessments will be conducted before the
participants will be randomised (1:1) to two groups (supervised PFMT
or attention-control massage treatment), using simple randomisation
(See Fig. 1 for the trial ﬂow). A data manager who has no other in-
volvement in the trial will produce a computer-generated sequence of
random group assignments (allocation sequence). The primary in-
vestigator (AU) who is blinded to the allocation sequence will enrol the
participants. Two secretaries with no other involvement in the trial will
manage the allocation sequence and assign the participants to the two
groups. The allocation sequence is kept in a locked cabinet and allo-
cation concealment is further secured by the use of sealed, opaque,
numbered envelopes prepared by the two secretaries. Finally, partici-
pants will be asked repeatedly not to reveal the group allocation to the
investigators and outcome assessors.
2.4. Interventions
2.4.1. Conservative treatment program (identical in both trial arms)
Both trial groups will receive a conservative treatment program
consisting of standard information and guidance by one of three nurses
specialized in faecal incontinence. All three nurses will be blinded to
the allocation to trial arms. The program consists of standard advice
about diet and ﬂuid intake and the use of ﬁbre supplements. If appro-
priate, the nurses will inform the participants about optimising bowel-
emptying by the use of laxatives with local eﬀect in the rectum (gly-
cerol) and/or use of antidiarrhoeal medication (loperamide). The con-
servative treatment will be delivered at the ﬁrst visit to the outpatient
clinic at the Department of Surgical and Medical Gastroenterology be-
fore inclusion in the trial. The information is followed up by a telephone
call by the nurse after approximately one month.
2.4.2. Settings and distribution of interventions
In addition to the conservative treatment program the participants
in both groups will receive their allocated intervention treatment. The
treatments in both groups will be delivered as individual face-to face
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visits at the department of Physiotherapy- and Occupational Therapy at
Copenhagen University Hospital and will be distributed over 16 weeks,
with treatment oﬀered in week 0, 2, 5, 8, 12 and 16 (+/−1 week). The
physiotherapists delivering the treatments will not be involved in the
assessment of outcomes.
2.4.3. Supervised pelvic ﬂoor muscle training
In addition to the conservative treatment program, the participants
in the PFMT group will receive six individual treatments of 45 min
consisting of individually supervised PFMT. The supervised PFMT will
be given by one of two physiotherapists specialised in faecal incon-
tinence and pelvic ﬂoor disorders. Both of them have over 10 years of
experience in treating pelvic ﬂoor disorders. At the ﬁrst visit, the par-
ticipants receive information about the anatomy and function of the
pelvic ﬂoor muscles by the use of images and a model of the pelvis.
They receive verbal instructions on how to perform a correct pelvic
ﬂoor muscle contraction and correct contractions will also be taught by
digital vaginal and rectal examination. In each session, the participants
receive an examination of the function of their pelvic ﬂoor muscles by a
digital vaginal and rectal examination. The pelvic ﬂoor muscles and the
external anal sphincter strength will be assessed according to the
Modiﬁed Oxford Score (ranging 0–5) and endurance of a submaximal
contraction will be determined [26]. The function of the pelvic ﬂoor
muscles will be assessed with intra-anal electromyography (EMG)-bio-
feedback using the U-control EMG-trainer and an anal probe from
Thought Technology Ltd, Canada. This ‘strength biofeedback training’
will be used to give the participants visual and auditory feedback on a
contraction in order to enhance the awareness, strength and endurance
of a correct pelvic ﬂoor muscle contraction [13,17–19,27]. The bio-
feedback assessment will be conducted with the participant in a lying
position and, from the second visit, with the participant in a lying,
sitting and standing position. Static and dynamic endurance will be
determined in all positions, as will the ability to perform a pelvic ﬂoor
muscle contraction before and during coughing, transfers, lifting and
walking. According to the ﬁndings from the physiotherapeutic ex-
amination, a home training program is prepared. The training program
will be individually adapted according to the abilities of each partici-
pant. Participants will be instructed in submaximal contractions and
relaxation of the muscles between contractions. Submaximal contrac-
tions are chosen to ensure a correct pelvic ﬂoor muscle contraction
Fig. 1. Trial ﬂow diagram. Abbreviations: FISI:
Fecal Incontinence Severity Index, FIQL: Fecal
Incontinence Quality of Life Scale; PGI-I: Patient
Global Impression of Improvement Scale.
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where participants are able to breathe freely and avoid activation of
muscle synergists like the gluteal, thigh or abdominal muscles. The
training program consists of three sets of 10 pelvic ﬂoor muscles con-
tractions sustained for up to 10 s and two sets of three contractions
sustained for up to 30 s. Participants will be instructed in a 1-min rest
between each set and between each of the 30 s contractions. Partici-
pants with low muscular endurance will be instructed to hold the
contractions according to the ﬁndings from the physiotherapeutic ex-
amination. For example, a participant with low muscular endurance
could be instructed to perform six sets of ﬁve contractions sustained for
5 s and then increase the duration and number of the contractions in
each set until he/she is able to perform the described program. Parti-
cipants who experience diﬃculties in performing a correct pelvic ﬂoor
muscle contraction will be instructed to check their contraction by
palpation at the anus and/or perineum when training at home in order
to achieve a correct contraction. The participants will be encouraged to
perform the training program at home on a daily basis. They will also
be taught to contract the pelvic ﬂoor muscles in response to faecal ur-
gency and in situations with increased abdominal pressure. Participants
will receive written training materials with explanations and illustra-
tions along with the verbally and digitally provided instructions (See
Fig. 2 for the illustrations explaining a correct pelvic ﬂoor muscle
contraction and Additional ﬁle 2 for the training materials).
The participants will be instructed to ﬁll out a training diary (See
Additional ﬁle 3) which also contains their individual home training
program. The training diary is used as a motivational tool and to
quantify training adherence. At each follow-up visit, the training diary
will be evaluated and any problems will be discussed with the phy-
siotherapist. To achieve overload of the pelvic ﬂoor muscles, the
training program will be progressed at each follow-up visit based on the
ﬁndings from the examination. As the participants make progress they
will be instructed to perform the exercises in diﬀerent body positions
such as sitting, bending forward and standing and during movements
such as transfers, lifting, walking and coughing. For an overview of the
content of the physiotherapeutic treatment, see Table 1.
2.4.4. Standardisation of the supervised PFMT
To achieve standardisation of supervised PFMT treatments, a
written protocol for the physiotherapeutic examinations and PFMT
program will be provided to the physiotherapists delivering the treat-
ments (See Additional ﬁle 4). This protocol contains a thorough de-
scription of the physiotherapeutic examination and the supervised
PFMT to be delivered at each visit with the physiotherapist. The phy-
siotherapists will be instructed in the use of this protocol before trial
start and adherence to the protocol will be recorded by the phy-
siotherapists ﬁlling in a case report form for each visit. If the phy-
siotherapists should have any clarifying questions about conducting the
intervention during the trial, they will be able to contact the primary
investigator anytime.
2.4.5. Attention-control massage treatment
The attention control group will receive the same conservative
treatment as the PFMT group, but instead of the supervised PFMT, they
will receive six treatments of 30 min consisting of massage of the neck
and back. The participants in the attention-control group will be given
no instructions in PFMT, but, on the other hand, they will not be asked
to refrain from performing PFMT on their own. The attention-control
massage treatment is chosen to give the participants in the attention-
control group the same number of visits and approximately the same
amount of attention from the health care professional. Moreover, we
consider the massage treatment to represent an inactive control treat-
ment, since it is shown not to improve urinary incontinence [28], a
condition that shares many of the known risk factors for faecal incon-
tinence [29].
Fig. 2. Illustrations from the written training materials illustrating a correct pelvic ﬂoor muscle contraction for a) women and b) men. Copyright: JohannesBojesen.com. For the complete
written training materials please see Additional ﬁle 2 for the training materials and Additional ﬁle 3 for the training diary.
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2.5. Blinding
2.5.1. Blinding of participants
Given the nature of the intervention and the attention-control
treatment, it is not possible to blind the participants or the phy-
siotherapists delivering the PFMT. All three nurses delivering the con-
servative treatment will be blinded to the allocation to trial arms. All
investigators, health care providers and outcome assessors are thor-
oughly instructed not to reveal to the participants that we expect the
supervised PFMT to be more eﬀective than the attention-control mas-
sage treatment. The treatments are presented as equal both in the
written and verbal information given at enrolment and at follow-ups.
Thus attempts are made to blind the participants to the trial hypothesis
[30].
2.5.2. Blinding of researchers and outcome assessors
The primary investigator (AU) enrolling the participants and col-
lecting baseline data (before randomisation) is blinded with respect to
group allocation. The research nurse (ID) conducting the anorectal
manometry and rectal capacity measurements at baseline (before ran-
domisation) and at the 16-week follow-up remains blinded to group
allocation. She is also blinded when handling the 16-week follow-up
questionnaires (primary and secondary outcomes at the primary end-
point). The colon and rectal surgeon (MS) conducting the examination
and endoanal ultrasound investigation at the 16-week follow-up is also
blinded to group allocation. Thus, all outcome assessors are blinded
with respect to group allocation. All data will be entered blinded and
validated using double entry.
2.6. Baseline data
After the participants have signed the informed consent form, the
primary investigator (AU) will collect the baseline data and distribute a
14-day bowel diary. Baseline data consists of: demographic background
information, a medical history with emphasis on the history of faecal
incontinence and known risk factors for faecal incontinence and for the
women an obstetric history. The participants ﬁll out validated ques-
tionnaires measuring severity of faecal incontinence and condition-
speciﬁc quality of life: The Fecal Incontinence Severity Index (FISI), the
Vaizey Incontinence Score and the Fecal Incontinence Quality of Life
Scale (FIQL) (See Outcome measures below). If the participants should
have any clarifying questions in relation to ﬁlling out the ques-
tionnaires, they are allowed to ask the primary investigator. After 2–4
weeks, the participants return to the Department of Surgical and
Medical Gastroenterology. A research nurse blinded to group allocation
collects the 14-day bowel dairy and conducts an anorectal manometry
and rectal capacity measurements. The participants then go to a se-
cretary in the Department of Physiotherapy- and Occupational Therapy
who will perform the randomisation of the participants.(For trial ﬂow,
see Fig. 1).
2.7. Outcome measures
Outcome measures will be assessed at baseline before randomisa-
tion, within 14 days after completion of the 16-week PFMT treatment or
attention-control massage treatments (primary endpoint) and at follow-
up 36 months after completing the treatments (still ongoing) using both
patient-reported outcomes and objective outcomes. The participants
will complete self-reported questionnaires and a 14-day bowel diary.
Also, anorectal manometry, rectal capacity measurements and an en-
doanal ultrasound will be conducted. For a schedule of the outcome
measures, see Table 2, and for participant timeline, including a sche-
dule of visits, events and data collection, see Table 3.
2.7.1. Primary outcome
The Patient Global Impression of Improvement Scale (PGI-I) [31] is
used as the primary eﬃcacy outcome measure. The scale is validated to
measure subjective treatment eﬀect in relation to urinary incontinence
[31] and pelvic organ prolapse [32]. The scale is a self-rated assessment
of changes in incontinence symptoms after treatment. The participants
are asked to compare their faecal incontinence symptoms before and
after the 16 weeks of treatment and to rate the degree of changes in
their symptoms. On a seven-point Likert scale, they indicate if their
incontinence symptoms after the 16 weeks of treatment are: very much
better, much better, a little better, unchanged, a little worse, much
worse or very much worse compared to the period prior to the trial
[31]. This scale is chosen since faecal incontinence is a symptom pri-
marily aﬀecting quality of life. On this basis, it is argued that treatment
eﬃcacy in people with faecal incontinence is best measured by the
person's subjective impression of symptoms (e.g. PGI-I) and by mea-
sures of condition-speciﬁc quality of life [33,34].
Table 1
Supervised Pelvic ﬂoor muscle training (PFMT).
Training week 0 Training week 2 Training week 5 Training week 8 Training week 12 Training week 16
45 min supervised PFMT + + + + + +
Digital vaginal and rectal examination + + + + + +
Correct contraction taught digitally + + + + + +
Biofeedback in lying position + + + + + +
Biofeedback in sitting and standing position + + + + +
Preparation of an individual home training program +
Progression of the individual home training program + + + + +
Motivational training-dairy review + + + + +
Collection of adherence data (training dairy) + + + + +
Table 2
Data collection/outcome measures.
Variable First
baseline
visit
Second
baseline visit
16-week
follow-up
36-month
follow-up
Demographic data +
Medical history +
Obstetric history +
Incontinence history +
PGI-I (primary
outcome)
+ +
Vaizey Incontinence
Score
+ + +
FISI + + +
FIQL + + +
14 days bowel dairy + +
Anorectal manometry + +
Rectal capacity
measurements
+ +
Endoanal ultrasound +
Abbreviations: FISI: Fecal Incontinence Severity Index, FIQL: Fecal Incontinence Quality
of Life Scale: PGI-I: Patient Global Impression of Improvement Scale.
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2.7.2. Secondary outcomes
2.7.2.1. The following outcome measures are the secondary
outcomes. Vaizey Incontinence Score: This is a validated summary
scale measuring severity of faecal incontinence, ranging from 0 – 24,
0 = complete continence, 24 = complete incontinence [35]. The scale
distinguishes between incontinence for ﬂatus, thin and formed stool.
Participants rate the frequency of each incontinence item in ﬁve
categories with frequencies ranging from less than once monthly to
daily. The presence of faecal urgency, use of pads and medication and
changes in life style in relation to faecal incontinence is also registered
[35].
Fecal Incontinence Severity Index (FISI): FISI is a validated severity
scale for faecal incontinence ranging from 0 – 61, 0 = complete con-
tinence, 61 = complete incontinence [36]. The scale distinguishes
between incontinence for gas, mucus, liquid and solid stool. Partici-
pants rate the frequency of each incontinence item in six categories.
Frequencies range from one to three times per month to two or more
times per day. Values for all categories are summed. The values are
weighted and reﬂect patients' subjective impression of severity. In this
trial, the patient-weighted scores are used [36].
Fecal Incontinence Quality of Life Scale (FIQL): FIQL is a validated
condition-speciﬁc quality of life Scale [33,37]. The Scale consists of 29
questions divided into four sub-scales: Lifestyle, Coping/behaviour,
Depression/self-perception and Embarrassment [37]. Items are gen-
erally scored on a four-point Likert scale ranging from ‘most of the time’
to ‘none of the time’ or from ‘strongly agree’ to ‘strongly disagree’. The
values in each subscale are summed and divided by the number of items
in the subscale. Each subscale range from 1 – 4, 1 = worst quality of
life, 4 = best quality of life.
All four of the PGI-I, the Vaizey Incontinence Score, the FISI and the
FIQL are validated in their original language, but have not been com-
prehensively validated for a Danish population. In this trial, we use the
Danish versions of the questionnaires that are generally used in
Denmark, which have only been linguistically validated.
Bowel diary: The participants ﬁll out a paper bowel dairy for 14
days where they report the number of stools, episodes of faecal urgency,
soiling and incontinence as well as the use of pads and laxatives.
Limitations in daily life due to faecal incontinence are also reported.
The participants are instructed to ﬁll out the diary at the end of the day
or to use real time assessment during the day by their own choice [38].
Anorectal manometry and rectal capacity measurements: A specia-
lised nurse (ID) will conduct anorectal manometry and rectal capacity
measurements. She has over 10 years of experience in conducting these
investigations. All measurements are recorded with the physiologic
recorder Polygraf ID from Medtronic, Denmark using the Polygram NET
software, Medtronic, Denmark. Anorectal manometry is performed to
measure anal sphincter pressures to get an objective evaluation of the
function of the pelvic ﬂoor muscles and rectum capacity. By this, ob-
jective changes after the treatments can be documented [39,40]. The
investigation is conducted by the water perfused catheter technique
using a single-use anorectal 8ch catheter from Sandhill, USA. With the
participant lying in the left lateral position and hip ﬂexed to 90°, a
Table 3
Participant timeline.
Study period
Pre-allocation/enrolment Allocation Post-allocation
Time point Screening visit Information visit First baseline
visit
Second
baseline visit
Allocation Treatments in week 0,
2, 5, 8, 12 and 16
16-week follow-up
(Primary endpoint)
36-month
follow-up
Enrolment:
Eligibility screening + +
Verbal and written information + +
Informed consent +
Allocation +
Interventions:
PFMT +
Attention-control massage
treatment
+
Assessments:
Baseline variables
Demographic data +
Medical history +
Obstetric history +
Incontinence history +
Outcome variables
Self-reported questionnaires
PGI-I (Primary outcome) + +
Vaizey Incontinence Score + + +
FISI + + +
FIQL + + +
14-day bowel diary + +
Physiological measurements
Anorectal manometry + +
Rectal capacity
measurements
+ +
Endoanal ultrasound +
Adherence:
Adherence to PFMT-
intervention (Training
diary)
+
Abbreviations: FISI: Fecal Incontinence Severity Index, FIQL: Fecal Incontinence Quality of Life Scale, PFMT: Pelvic ﬂoor muscle training, PGI-I: Patient Global Impression of
Improvement Scale.
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balloon catheter is inserted into the rectum. Resting pressure and
maximum squeeze increment pressure is determined. Both measures are
recorded in the high pressure zone using the pull through technique
[39]. Rectal capacity measurements of the rectum are performed by the
use of a single-use 4ch catheter from Sandhill, USA. The catheter is
inserted into the rectum and then slowly inﬂated with air. Sensory
threshold is determined as the minimum volume of ﬁlling where a
rectal sensation is perceived. Urge sensation is determined as the vo-
lume associated with the initial urge to defecate and maximum toler-
ated volume is determined as the volume where the participants feel a
strong desire to defecate and feel pain or discomfort.
3D Endoanal ultrasound and gynaecological and rectal examination:
An experienced colon and rectal surgeon (MS) conducts a gynaecolo-
gical and rectal examination. To detect internal and/or external anal
sphincter defects, the examination is supplemented by endoanal ultra-
sonography. The investigation is conducted with the ultrasound system
Flex Focus 500 from BK Medical, Denmark using the anorectal 3D
transducer 2052, 13 MHz from BK Medical, Denmark. The system
provides a three-dimensional image of the sphincter complex and the
puborectal muscle. With the participant lying in the supine position, the
probe is inserted into the anal canal just above the level of the pub-
orectal muscle. The diﬀerent components of the anal sphincter complex
and the puborectal muscle are visualised and a 360-degree image is
created. Sphincter defects in the internal and/or external sphincter are
deﬁned as a gap in the muscle ring or a loss of muscle substance in a
range of more than 60°. The extension of sphincter defect is measured in
degrees.
2.7.3. Minimizing missing data
To minimise missing data for the primary endpoint, all participants
will be reminded about the 16-week assessment visit (primary end-
point) by a telephone call from the primary investigator 14 days before
the visit. At the same time, the participants will be encouraged to begin
ﬁlling out the bowel diary.
2.7.4. Deviations from the trial protocol and trial registration
Initially, a 12-month follow-up was planned and described in the
trial registry. For logistical reasons, however, we failed to perform the
12-month follow-up for the ﬁrst 15 participants. Because of this, we
decided to change the 12-month follow-up to 36 months. This will
enable us to perform a long-term outcome assessment for all included
participants. This change does not aﬀect the pre-speciﬁed primary
endpoint, that is, the participants' rating of changes in their incon-
tinence symptoms after 16 weeks of treatment measured by the PGI-I.
To achieve as high response rate as possible, we decided to restrict the
36-month follow-up measurement to the PGI-I, the Vaizey Incontinence
Score, the FISI and the FIQL. Additional questions about further treat-
ment for faecal incontinence since completion of the trial will be added
to the 36-months follow-up assessment, as will questions about the
current amount of PFMT. The follow-up questionnaire will be handled
by post. Reminders will be sent to non-responders after 4 weeks, and
followed up with telephone calls.
Originally, it was planned to measure maximum squeeze duration as
a part of the anorectal manometry investigation. Maximum squeeze
duration is deﬁned as the time the participants could hold a squeeze
from maximum increment squeeze pressure to a drop of 50% of max-
imum increment squeeze pressure. The maximum squeeze duration was
measured three times with a stationary probe for up to a maximum of
30 s. The participants had 1 min's rest between each of the three trials.
It was planned to determine maximum squeeze duration as the average
of these three trials. As a part of the ongoing data quality check during
the data collection it became clear that it was diﬃcult to determine the
time duration of a maximum squeeze with the stationary probe.
Therefore, it was decided to not use the data for maximum squeeze
duration in further analysis.
2.8. Sample size
The sample size is calculated in relation to the PGI-I (primary out-
come). Based on previous ﬁndings in the literature, we hypothesise that
30% of the participants in the attention-control group [41–43] and 60%
of the participants in the PFMT group [13,19,44] will achieve im-
provement in relation to their faecal incontinence symptoms. Im-
provement is deﬁned as participants reporting ‘very much better’,
‘much better’ or ‘a little better’ using the PGI-I. Based on a binomial
distribution, we will need a sample size of 84 to show this clinically
relevant diﬀerence in treatment eﬀect between groups using a statis-
tical power of 80% and a signiﬁcance level of 5% (two-tailed). To ac-
count for a dropout rate of 16%, we aim to include 100 participants.
2.9. Data management
The data will be handled in accordance with the rules from the
Danish Data Protection Agency. All data will be collected on paper case
report forms that will contain no information on group allocation. An
exception to this will be data from the training diaries and case report
forms from the supervised PFMT-treatments, as this data will inherently
only exists for the PFMT-group and will be stored separately. After
collection, all case report forms will be checked for data quality and
missing values and will be stored in a locked cabinet to which only the
primary investigator has access. All data will be double-entered in
EpiData Entry version 3.1, Epidata Associations, Odense, Denmark. A
standard coding manual describing data entry is developed to reduce
errors and ensure comprehension under the analyses. Data entry will be
validated by checks for valid values and range checks. For the analyses,
the data will be exported to SAS Enterprise Guide 7.1, SAS institute Inc.,
Cary, NC, USA. The electronic database and analyses will be stored on a
secure computer server with personal log-in access authorised by the
primary investigator. The primary investigator will have access to the
full data set (blinded to group allocation) and co-investigators will be
given access when needed. After completion of the trial, all data and
trial documents will be archived by the primary investigator and stored
for 5 years at the Department of Physio- and Occupational Therapy at
Hvidovre University Hospital.
2.10. Statistical analysis plan
2.10.1. Recruitment and withdrawals
Recruitment rates and numbers of withdrawals and dropouts will be
reported along with reasons for exclusions, dropouts and withdrawals.
2.10.2. Baseline data
Baseline data will be presented as medians (with range) for con-
tinuous data. Categorical variables will be presented as frequencies and
percentages.
2.10.3. Session attendance and adherence
Session attendance in both groups will be presented as median
number of consultations (with range) with the physiotherapist.
Adherence to the pelvic ﬂoor muscle home training program will be
presented as median number of days (with range) and the corre-
sponding percentage, where the participants have noted training in the
diary. Adherence will also be calculated as the percentage of partici-
pants who have attended at least four of six consultations with the
physiotherapist, and at the same time have trained on at least 70% of
the possible 112 training days corresponding to approximately 5
training days per week on average. We consider this as a minimum
exposure for the per-protocol analysis.
2.10.4. Primary analysis of the primary outcome
The purpose of the primary analysis is to test the trial hypothesis
that supervised PFMT in combination with conservative treatment is
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superior to attention-control treatment and conservative treatment
alone in the treatment of faecal incontinence. The data for the primary
outcome, the participants' ratings of changes in their incontinence
symptoms at PGI-I after 16 weeks of treatment, will be analysed in
order to compare diﬀerences in treatment eﬀects between the two
groups.
Estimates of treatment eﬀect for the primary outcome will be cal-
culated using an ‘intention to treat’ analysis, including all randomised
participants regardless of adherence to the intervention and dropouts.
To create a full analysis data set, missing data for the primary outcome
will be imputed with a score of ‘unchanged’ in both groups. The pri-
mary analysis will be carried out using logistic regression with PGI-I
scores as the dependent variable. The PGI-I outcomes will be dichot-
omised into symptoms improvement (PGI-I scores of ‘very much better’,
‘much better’ or a ‘little better’) or unchanged/worsening symptoms
(PGI-I scores of ‘unchanged’, ‘a little worse’, ‘much worse’ or ‘very much
worse’). By this we can calculate the odds ratio for participants in the
PFMT-group reporting improvement of their incontinence condition
after 16 weeks of treatment corresponding to the three upper values at
the PGI-I (very much better, much better, a little better). The attention-
control group will be the reference group.
The estimates of the size of treatment eﬀect will be presented along
with 95% conﬁdence intervals and actual p-values. Levels of sig-
niﬁcance will be set at 0.05. The independent variable will be group
allocation. The primary analysis will be unadjusted.
2.10.5. Secondary analysis of the primary outcome
We will report the absolute numbers and proportions of participants
in each group stating each of the seven categories at the PGI-I: very
much better, much better, a little better, unchanged, a little worse,
much worse or very much worse and the prevalence of participants
reporting either improvement in their incontinence condition (a PGI-I
score of ‘very much better’, ‘much better’ or a ‘little better’) or un-
changed/worsening symptoms (a PGI-I score of ‘unchanged’, ‘a little
worse’, ‘much worse’ or ‘very much worse’).
Also a proportional odds model will be ﬁtted with the PGI-I scores as
outcome including all seven categories. In case the proportional odds
assumption is not fulﬁlled a multinomial logit model will be ﬁtted
comparing the PFMT group and the attention-control group. In the case
that a multinomial logit model is necessary, then if there is fewer than
10 observations in one category this category will be grouped together
to the category next to in the less extreme direction.
Sensitivity analyses for the primary outcome will be made if missing
values appear to depend on group allocation or if over 10% of the
participants have missing values for the primary outcome. In these
cases, the primary analysis will be supplemented by sensitivity analyses
using worst case and best case scenarios. In the worst case scenario,
missing values for the attention-control group will be imputed with a
score of ‘very much better’. If no participants (in either group) have
scored ‘very much better’ we will impute the most extreme positive
value observed. For the PFMT group missing, values will be imputed
with a score of ‘very much worse’ or if no participants have scored ‘very
much worse’, with the most extreme negative value observed. In con-
trast, in the best case scenario, missing values will be imputed, with a
score of ‘very much worse’ for the attention-control group and a score of
‘very much better’ for the PFMT group or the most extreme values
observed.
In order to examine the inﬂuence of potential confounders and
modiﬁers, multiple analyses will be conducted. The modiﬁers that will
be taken into account are signiﬁcant baseline diﬀerences, use of anti-
diarrhoeal medication and use of ﬁbre supplements at baseline, de-
tected anal sphincter injuries at endoanal ultrasound, stool consistency,
incontinence type (urgency, passive or both) and the presence of ur-
inary incontinence. The modiﬁers will be modelled by adding interac-
tion terms to the multiple analyses. In cases of statistical interaction, the
eﬀect of the intervention will be reported in strata representing each
level of the modifying variable along with the main eﬀect of the
treatment groups.
To account for diﬀerences in adherence to the PFMT intervention, a
per-protocol logistic regression analysis will be undertaken following
the principles outlined above. This per protocol analysis will include
participants who have attended at least four of six consultations with
the physiotherapist, and who at the same time, have documented
training on at least 70% of the possible training days corresponding to
approximately 5 training days per week on average.
2.10.6. Analyses of secondary outcomes
Analyses of secondary outcomes supporting the primary outcome:
The secondary outcome measuring condition-speciﬁc quality of life, the
FIQL,-and the two secondary outcomes measuring faecal incontinence
severity, the FISI and the Vaizey Incontinence Score, are considered
supportive for the primary analysis of the primary outcome. All other
secondary analyses are considered explorative secondary analyses. The
three supportive outcome measures will be analysed using multiple
linear regression analyses with group allocation as the independent
variable. Investigation of confounders and modiﬁers will be conducted
the same way as for the primary analysis. Changes from baseline to end
of treatment (after 16 weeks) will be reported as estimates of mean
diﬀerence in treatment eﬀect between groups. For the FIQL, the mean
diﬀerences in change between groups will be reported within the four
subscales: Lifestyle, Coping/behaviour, Depression/self-perception and
Embarrassment. The analyses for the three supportive outcomes will be
conducted both according to the intention to treat principle and as per-
protocol analyses as outlined above. Missing data will be handled by
multiple imputation.
Explorative analyses of the secondary outcomes: Data from the an-
orectal manometry investigations, rectal capacity measurements and
continuous data from the bowel diary (number of stools and incon-
tinence episodes) will be conducted as per protocol analyses using
multiple linear regression analyses with group allocation as the in-
dependent variable. Results will be reported as mean diﬀerences be-
tween groups from baseline to end of treatment (after 16 weeks).
Missing data will be handled by multiple imputation. As paper diaries
are prone to low compliance and missing data [42,45], we will conduct
a sensitivity analysis in case of missing data exceeds 10% for the bowel
diaries or the missing data appear not to be missing at random. In this
analysis, missing values will be imputed using multiple imputation for
variables where missing values are jugded to be missing at random (no
speciﬁc pattern in the missing data). But at the same time, for variables
where missing values are judged not to be missing at random (data are
generally missing for a speciﬁc items unless that speciﬁc item is scored
positively) missing values will be replaced with a score of zero for
numeric questions and a negative answer for yes/no questions.
All estimates of treatment eﬀect will be presented as mean diﬀer-
ences in change between groups with 95% conﬁdence intervals. All
regression models will be controlled for goodness-of-ﬁt by evaluation of
whether the data meet the assumptions of linearity, normal distribution
and variance homogeneity. Normal distribution of the residuals will be
checked by visual inspection of residual plots, scatterplots and histo-
grams. Remodelling will be performed when appropriate.
Statistical analyses will be performed using SAS Enterprise Guide
7.1 SAS institute Inc., Cary, NC, USA. All analyses will be conducted by
researchers blinded for group allocation. For all statistical tests the
actual two-sided p-value will be reported, values below 0.05 will be
considered statistically signiﬁcant.
2.10.7. Analyses for the secondary endpoint at the 36-month follow-up
Analyses of the PGI-I, the Vaizey Incontinence Score, the FISI and
the FIQL at the 36-month follow-up will be conducted in the same way
as for the primary endpoint as described above.
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2.11. Data monitoring
It is decided to not set up a data monitoring committee for the trial
because both the supervised PFMT and the attention-control treatment
are regarded as safe interventions [18,46]. No interim analysis or
stopping guidelines will be applied to the trial. All physiotherapists and
outcome assessors are instructed to report any adverse events during
the trial to the primary investigator via weekly conferences that allow
discussion of the conduct of the trial and any adverse events. All ad-
verse events will be reported annually to the Health Research Ethics
Committee and all serious adverse events will be reported immediately.
Since the trial is not investigating clinical products or drugs, the trial is
not covered by the Good Clinical Practice regulations. Therefore, no
regulatory auditing of the trial is prescribed by law. The trial can be
subject to unannounced audits by the local regional Health Research
Ethics Committee or Danish Data Protection Agency.
3. Discussion
This trial will show whether supervised PFMT in combination with
conservative treatment is superior to attention-control massage treat-
ment and conservative treatment in patients with faecal incontinence.
This will be based on changes in faecal incontinence symptoms after 16
weeks of treatment using the PGI-I. The eﬃcacy of PFMT and bio-
feedback training for faecal incontinence is unclear. Previous trials have
lacked an attention-control group in the form of a non-training com-
parator. This trial adds an attention-control group receiving the same
number of visits and approximately the same amount of attention as the
PFMT group. We consider the attention-control massage treatment to
represent an inactive control treatment, since it has been shown not to
improve urinary incontinence [28] which shares many of the known
risk factors for faecal incontinence. Adding this attention-control group
will enable us to evaluate the true eﬃcacy of supervised PFMT con-
trolled for the placebo eﬀect associated with attention given by the
healthcare professional. This knowledge will help to clarify the role of
pelvic ﬂoor muscle training for faecal incontinence and permit evi-
dence-based recommendations about PFMT as a part of the ﬁrst-line
treatment for faecal incontinence.
In this trial, we have chosen the individualised, supervised approach
to PFMT, including palpation of a correct contraction. This is because, it
is shown that up to 40% of women with pelvic ﬂoor disorders fail to
achieve a correct pelvic ﬂoor muscle contraction after written or verbal
instructions alone [47,48]. This fact, along with individualised pro-
gression of the PFMT, can be challenging in a group setting.
It can be diﬃcult to blind participants and health care providers
when examining a physiotherapeutic intervention. In this trial, instead
we seek to blind the participants to the trial hypothesis. The partici-
pants are thus not informed, neither verbally nor in writing, that we
expect the supervised PFMT to be more eﬃcient than the attention-
control massage treatment. It is decided not to ask the attention-control
group to refrain from performing PFMT on their own. Attempts to re-
strict the attention-control group from performing PFMT can reveal the
study hypothesis and at the same time it is not possible to control
whether the participants in the attention-control group actually refrain
from performing PFMT.
The optimal patient-reported outcome for evaluating treatment ef-
ﬁcacy for faecal incontinence is debated [49]. In this trial, the PGI-I is
chosen as the primary outcome. This is because it is recommended to
measure treatment eﬃcacy by eliciting the person's subjective im-
pression of symptoms after treatment [33,34]. Other trials have used
the Vaizey Incontinence Score as their primary outcome. We decided
not to do so because the Vaizey Incontinence Score is shown to contain
items insensitive to treatment eﬀect [50] and has been criticised for
mixing measurement of severity, social impact and coping strategies
[33,49].
In the absence of an optimal patient-reported outcome for
measuring faecal incontinence, we decided to include the three sec-
ondary patient-reported outcomes: the Vaizey Incontinence Score, the
FISI and the FIQL, all of which we consider to be supportive of the
primary outcome. This is in line with the recommendations of including
both severity measures, subjective rating of improvements and condi-
tion-speciﬁc quality of life measures when evaluating treatment eﬃ-
cacy in faecal incontinence [33,49]. It is a weakness that the Danish
versions of the PGI-I, the Vaizey Incontinence Score, the FISI and the
FIQL used in this trial are not comprehensively validated in a Danish
population, but only linguistically validated. The questionnaires are all
comprehensively validated in their original language. It is un-
fortunately beyond the scope of this trial to validate the Danish lan-
guage versions of these patient-reported outcomes before conducting
the trial. Instead, we use the Danish versions that are generally used in
Denmark.
Trial status
To date, we have enrolled 102 participants in the trial and have
completed the baseline and 16-week assessment (primary endpoint).
Hence, trial recruitment has stopped, but data collection for the 36-
month outcome assessment will continue until June 2019. The data are
currently being cleaned and double-entered (no data lock), no analyses
have been made, and the treatment group allocation remains blinded.
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